The FDA had said intranasal abuse of the opioid-based product was a relevant concern. KemPharm said the Drug Enforcement Administration (DEA) intends to schedule Apadaz as a C-II product. A C-II drug is considered to have a high potential for abuse, according to the DEA's website. Investors have ...

Read more